Understanding PD-1 Inhibitors in Hodgkin Lymphoma: A Guide for the Oncology Advanced Practitioner
- 1From The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract
Classical Hodgkin lymphoma (cHL) is a rare cancer, usually affecting young adults and those over 55 years. A subset of patients experiences relapsed or refractory disease, which remains a treatment challenge. Understanding molecular biomarkers, especially programmed cell death protein 1 (PD-1), is increasingly important for developing new therapies. PD-1 is an immune checkpoint that controls T-cell activation, and its overexpression in cHL enables tumors to evade immune detection. Immune checkpoint inhibitors, such as nivolumab, have shown promise in treating relapsed or refractory cHL by blocking PD-1 and restoring immune responses. This developing landscape requires oncology advanced practitioners to be aware of PD-1 as both a therapeutic target and a predictive biomarker, allowing for personalized treatment plans. Additionally, ensuring equitable access to these innovations remains a major concern, particularly for underserved populations. Oncology advanced practitioners play a critical role in closing care gaps, advocating for broader access, and maintaining ethical standards.
Related
- Burkitt lymphoma: current understanding, unmet needs, and research directions∗
- Understanding the Immune Response Changes to Clinical Interventions for Epstein–Barr Virus Infection Prior to Lymphoma Development in Children After Organ Transplants (UNEARTH)
- Community-Based Cardio-Oncology Model for Hypertension Management in Gynecologic Oncology Patients on VEGF Inhibitors
- Understanding Patient Perspectives and Acceptability of Integrative Naturopathic Oncology in Metastatic Cancer.
- Inclusive Leadership and Psychological Safety Among Oncology Advanced Practice Providers: Implications for Team-Based Practice
BibTeX
@article{guerrero2026understanding,
title = {{Understanding PD-1 Inhibitors in Hodgkin Lymphoma: A Guide for the Oncology Advanced Practitioner}},
author = {Maria D. Guerrero and Van Nguyen},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
month = sep,
doi = {10.6004/jadpro.2026.17.5.3},
url = {https://doi.org/10.6004/jadpro.2026.17.5.3},
note = {CC BY-NC-ND 3.0},
}
RIS
TY - JOUR
TI - Understanding PD-1 Inhibitors in Hodgkin Lymphoma: A Guide for the Oncology Advanced Practitioner
AU - Maria D. Guerrero
AU - Van Nguyen
PY - 2026
DA - 2026/09/01
JO - Journal of the Advanced Practitioner in Oncology
DO - 10.6004/jadpro.2026.17.5.3
UR - https://doi.org/10.6004/jadpro.2026.17.5.3
AB - Classical Hodgkin lymphoma (cHL) is a rare cancer, usually affecting young adults and those over 55 years. A subset of patients experiences relapsed or refractory disease, which remains a treatment challenge. Understanding molecular biomarkers, especially programmed cell death protein 1 (PD-1), is increasingly important for developing new therapies. PD-1 is an immune checkpoint that controls T-cell activation, and its overexpression in cHL enables tumors to evade immune detection. Immune checkpoint inhibitors, such as nivolumab, have shown promise in treating relapsed or refractory cHL by blocking PD-1 and restoring immune responses. This developing landscape requires oncology advanced practitioners to be aware of PD-1 as both a therapeutic target and a predictive biomarker, allowing for personalized treatment plans. Additionally, ensuring equitable access to these innovations remains a major concern, particularly for underserved populations. Oncology advanced practitioners play a critical role in closing care gaps, advocating for broader access, and maintaining ethical standards.
SN - 2150-0878
SN - 2150-0886
ER -